Ionis Pharmaceuticals Inc. (IONS) exhibits 96.0% gross margins and -20.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 7.2% implied options volatility.
Sustained 96.0% gross profitability converts into -40.4% operating margin and -20.9% ROIC, outpacing sector cost of capital.
ROIC: -20.9% // GM: 96.0%YoY revenue trajectory of +33.8% paired with -4.34% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +33.8% // FCF YLD: -4.34%Altman Z-Score of 1.08 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.08 // F-SCORE: 5/9Trading at 24.0x trailing P/E (22.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.2% implied move with a 0.97 put/call ratio around $44.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.97Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -40.4% net margins.
NET MARGIN: -40.4% // D/E: 2.72x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for IONS & activate live FRED threshold breach alerts.